MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

64.68
+0.96
+1.51%
After Hours: 64.68 0 0.00% 16:09 12/10 EST
OPEN
63.73
PREV CLOSE
63.72
HIGH
64.88
LOW
63.43
VOLUME
156.86K
TURNOVER
--
52 WEEK HIGH
106.80
52 WEEK LOW
57.15
MARKET CAP
1.28B
P/E (TTM)
29.13
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ENTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ENTA News

  • Should You Worry About Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pay Cheque?
  • Simply Wall St..1d ago
  • Edited Transcript of ENTA earnings conference call or presentation 21-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2d ago
  • Benzinga's Top Upgrades, Downgrades For November 22, 2019
  • Benzinga.11/22 15:03
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Name
Price
%Change

About ENTA

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
More

Webull offers Enanta Pharmaceuticals Inc (ENTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.